Kiora Pharmaceuticals Inc
Veridion Score
Composite trend over time
Why is KPRX moving today?
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for KPRX.
KPRX insider activity
Kiora Pharmaceuticals Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$8K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-02 | 2026-04-01 | Tosca Melissa | Insider | sell | $1.95 | 929 | 26,975 | $2K | SEC Form 4 |
| 2026-04-02 | 2026-04-01 | Daniels Eric Joseph | Insider | sell | $1.95 | 929 | 31,741 | $2K | SEC Form 4 |
| 2026-04-02 | 2026-04-01 | Strem Brian M. | Insider | sell | $1.95 | 1,906 | 60,692 | $4K | SEC Form 4 |
| 2026-03-06 | 2026-03-03 | Daniels Eric Joseph | Insider | sell | $2.02 | 238 | 26,137 | $481 | SEC Form 4 |
| 2026-03-06 | 2026-03-03 | Strem Brian M. | Insider | sell | $2.02 | 238 | 45,865 | $481 | SEC Form 4 |
KPRX contract awards, year to date.
Public federal awards linked to this ticker.
KPRX lobbying filings, year to date.
Registered lobbying filings matched to Kiora Pharmaceuticals Inc.